Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 2/2013

01-02-2013 | Research Article

Ultrasound-assisted endocavitary HDR-Ir192 brachytherapy for unresectable locally advanced uterine cervix carcinoma: retrospective analysis focusing the efficacy and tolerability

Authors: Georgios V. Koukourakis, Anthoula Miliadou, Ioannis Tsalafoutas, Elisavet Geli, Anastasia Sotiropoulou-Lontou

Published in: Clinical and Translational Oncology | Issue 2/2013

Login to get access

Abstract

Purpose

To evaluate the impact of uterine cavity’s ultrasound to final selected length of intracavitary tandem. The efficacy and tolerability of external beam radiation plus HDR-Ir192 brachytherapy in our cohort of patients were also estimated.

Materials and methods

48 women with locally advanced unresectable uterine cervix carcinoma were treated by HDR-Ir192 endocavitary brachytherapy between January 2007 and January 2009. The median age was 63 (range 38–74). The distribution according to Federation of Gynaecology and Obstetrics (FIGO) staging system was as follows: Stage IIB, 54.16 %; IIIA, 10.4 %; IIIB, 27.0 %; and IVA, 8.3 %. HDR intracavitary brachytherapy was given weekly, beginning at the last week of whole pelvis irradiation, with a dose of 7 Gy to point A for three to four fractions. The median overall treatment time was 50 days (range 42–73 days). The median follow-up time was 2.7 years (range 3 months to 4.9 years). Multivariate analysis was performed using the Cox regression proportional hazards model.

Results

The complete remission rate after radiotherapy was 93.75 % (45/48). The 5-year actuarial major complication rates (Grade 3 or above) were 6.3 % overall (2.1 % proctitis, 2.1 % cystitis and 2.1 % enteritis). Estimation of the length of uterine cavity by ultrasound helped decisively in the proper placement of the intrauterine tandem inserted.

Conclusions

Prior knowledge of the length of uterine cavity can facilitate the decisions regarding the proper insertion length of the tandem. Results of cervical cancer treatment with external beam radiation and HDR intracavitary brachytherapy in our hospital are encouraging.
Literature
1.
2.
Kapp KS, Stuecklschweiger GF, Kapp DS et al (1997) Carcinoma of the cervix: analysis of complications after primary external beam radiation and Ir-192 HDR brachytherapy. Radiother Oncol 42:143–153PubMedCrossRef
3.
Roman TN, Souhami L, Freeman CR et al (1991) High-dose-rate afterloading intracavitary therapy in carcinoma of the cervix. Int J Radiat Oncol Biol Phys 20:921–926PubMedCrossRef
4.
Lorvidhaya V, Tonusin A, Changwiwit W et al (2000) High-dose rate afterloading brachytherapy in carcinoma of the cervix: an experience of 1992 patients. Int J Radiat Oncol Biol Phys 46:1185–1191PubMedCrossRef
5.
Shigematsu Y, Nishiyama K, Masaki N et al (1983) Treatment of carcinoma of the uterine cervix by remote controlled afterloading intracavitary radiotherapy with high-dose rate: a comparative study with a low-dose rate system. Int J Radiat Oncol Biol Phys 9:351–356PubMedCrossRef
6.
Wang CJ, Leung SW, Chen HC et al (1997) High-dose-rate intracavitary brachytherapy (HDR-IC) in treatment of cervical cancer: 5-year results and implication of increased low-grade rectal complication on initiation of an HDR-IC fractionation scheme. Int J Radiat Oncol Biol Phys 38:391–398PubMedCrossRef
7.
Chen MS, Lin FJ, Hong CH et al (1991) High-dose-rate afterloading technique in the radiation treatment of uterine cervical cancer: 399 cases and 9 years experience in Taiwan. Int J Radiat Oncol Biol Phys 20:915–919PubMedCrossRef
8.
Eifel PJ (1992) High-dose-rate brachytherapy for carcinoma of the cervix: high tech or high risk? Int J Radiat Oncol Biol Phys 24:383–386PubMedCrossRef
9.
Petereit DG, Sarkaria JN, Potter DM et al (1999) High-dose-rate versus low-dose-rate brachytherapy in the treatment of cervical cancer: analysis of tumor recurrence—the University of Wisconsin experience. Int J Radiat Oncol Biol Phys 45:1267–1274PubMedCrossRef
10.
Petereit DG, Pearcey R (1999) Literature analysis of high dose rate brachytherapy fractionation schedules in the treatment of cervical cancer: is there an optimal fractionation schedule? Int J Radiat Oncol Biol Phys 43:359–366PubMedCrossRef
11.
ICRU report 38 (1985) Dose and volume specification for reporting intracavitary therapy in gynecology, International Commission on Radiation Units and Measurements, Bethesda, pp 1–20
12.
Pavy JJ, Denekamp J, Letschert J et al (1995) Late effects toxicity scoring: the SOMA scale. Radiother Oncol 35:11–15PubMedCrossRef
13.
Patel FD, Sharma SC, Negi PS et al (1994) Low dose rate vs. high dose rate brachytherapy in the treatment of carcinoma of the uterine cervix: a clinical trial. Int J Radiat Oncol Biol Phys 28:335–341PubMedCrossRef
14.
Hareyama M, Sakata KI, Oouchi A et al (2002) High-dose-rate versus low-dose-rate intracavitary therapy for carcinoma of the uterine cervix. Cancer 94:117–124PubMedCrossRef
15.
Choy D, Wong LC, Sham J et al (1993) Dose-tumor response for carcinoma of cervix: an analysis of 594 patients treated by radiotherapy. Gynecol Oncol 49:311–317PubMedCrossRef
16.
Perez CA, Grigsby PW, Lockett MA et al (1999) Radiation therapy morbidity in carcinoma of the uterine cervix: dosimetric and clinical correlation. Int J Radiat Oncol Biol Phys 44:855–866PubMedCrossRef
17.
Pechoux CL, Akine Y, Sumi M et al (1995) High dose rate brachytherapy for carcinoma of the uterine cervix: comparison of two different fractionation regimens. Int J Radiat Oncol Biol Phys 31:735–741PubMedCrossRef
18.
Girinski T, Pejovic-Lenfant MH, Bourhis J et al (1989) Prognostic value of hemoglobin concentrations and blood transfusion in advanced carcinoma of the cervix treated by radiation therapy: results of a retrospective study of 386 patients. Int J Radiat Oncol Biol Phys 16:37–42PubMedCrossRef
19.
Arai T, Nakano T, Morita S et al (1992) High dose rate remote afterloading intracavitary radiation therapy for carcinoma of the uterine cervix: a 20-year experience. Cancer 69:175–180PubMedCrossRef
20.
Selke P, Roman TN, Souhami L et al (1993) Treatment results of high dose rate brachytherapy in patients with carcinoma of the cervix. Int J Radiat Oncol Biol Phys 27:803–809PubMedCrossRef
21.
Perez CA, Kuske RR, Camel HM et al (1988) Analysis of pelvic tumor control and impact on survival in carcinoma of the uterine cervix treated with radiation therapy alone. Int J Radiat Oncol Biol Phys 14:613–621PubMedCrossRef
22.
Fagundes H, Perez CA, Grigsby PW et al (1992) Distant metastases after irradiation alone in carcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys 24:197–204PubMedCrossRef
23.
Ito H, Kutuki S, Nishiguchi I et al (1994) Radiotherapy for cervical cancer with high-dose rate brachytherapy correlation between tumor size, dose and failure. Radiother Oncol 31:240–247PubMedCrossRef
Metadata
Title
Ultrasound-assisted endocavitary HDR-Ir192 brachytherapy for unresectable locally advanced uterine cervix carcinoma: retrospective analysis focusing the efficacy and tolerability
Authors
Georgios V. Koukourakis
Anthoula Miliadou
Ioannis Tsalafoutas
Elisavet Geli
Anastasia Sotiropoulou-Lontou
Publication date
01-02-2013
Publisher
Springer Milan
Published in
Clinical and Translational Oncology / Issue 2/2013
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-012-0901-4

Other articles of this Issue 2/2013

Clinical and Translational Oncology 2/2013 Go to the issue

Research Article

Co-expression of MMP-14 and MMP-19 predicts poor survival in human glioma

Research Article

Multicenter validation of two nomograms to predict non-sentinel node involvement in breast cancer

Research Article

Sorafenib for non-selected patient population with advanced hepatocellular carcinoma: efficacy and safety data according to liver function

Educational Series – Blue Series

MYC oncogene in myeloid neoplasias

Educational Series – Red Series

Radiotherapy in conjunction with superficial and intracavitary hyperthermia for the treatment of solid tumors: survival and thermal parameters

Correspondence

CHEK2 c.1100delC mutation among non-BRCA1/2 Spanish hereditary breast cancer families
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits